Lupin, Astellas Settle Mirabegron Patent Dispute for USD 90 Million
Lupin Limited has reached a settlement and licensing agreement with Astellas Pharma and its group companies, bringing an end to the long-running patent infringement litigation related to the overactive bladder drug Mirabegron (marketed by Astellas as Myrbetriq).
Lupin said the agreement was signed by the company and its wholly owned US subsidiary, Lupin Pharmaceuticals, Inc., with Astellas Pharma, Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc.










